{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:38:57Z","timestamp":1781350737318,"version":"3.54.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Although initial surgical excision cures 95% of patients, a minority of cutaneous squamous cell carcinomas (cSCCs) are judged to be unresectable, either locally advanced or with unresectable regional lymph nodes or distant metastases. These patients are offered systemic treatments. Response rate to chemotherapy is relatively low and not durable, as well as the results obtained with epidermal growth factor inhibitors (EGFRi). Like other cutaneous tumors, cSCCs have high immunogenicity, driven by the high mutational burden, the ultraviolet signature, and the overexpressed tumor antigens. Two checkpoint inhibitors, cemiplimab and pembrolizumab, achieved high response rate and survival with fewer toxicities than other available systemic agents. These promising results prompted to investigate new combination strategies of systemic therapy and surgery or radiotherapy. Subgroup analysis showed promising role of immunotherapy to facilitate surgery in locally advanced cSCC and, in a small group of patients, long-term survivals without resection. However, some cSCCs treated with immunotherapy develop either early or late resistance, so new drugs and new combinations are in a clinical study to overcome the mechanism underpinning these resistances. The present review focuses on the progress with immunotherapy to date and on new therapeutic strategies for cSCC.<\/jats:p>","DOI":"10.3389\/fonc.2021.727027","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T06:09:59Z","timestamp":1641362999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives"],"prefix":"10.3389","volume":"11","author":[{"given":"Andrea","family":"Alberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bjoms.2014.01.015","article-title":"Management of Regional Metastatic Disease in Head and Neck Cutaneous Malignancy. Cutaneous Squamous Cell Carcinoma","volume":"52","author":"Gurney","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40257-016-0207-3","article-title":"Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease","volume":"17","author":"Burton","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","article-title":"Treatment of Advanced Squamous Cell Carcinoma of the Skin With Cisplatin, 5-Fluorouracil, and Bleomycin","volume":"66","author":"Sadek","year":"1990","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature","volume":"39","author":"Karkiwski","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.12788\/j.sder.2019.010","article-title":"Systemic Therapy for Advanced Cutaneous Squamous Cell Carcinoma Semin Cutan","volume":"38","author":"Fitzgerald","year":"2019","journal-title":"Med Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.13.2.375","article-title":"Normalization of EGFR Mrnalevels Following Restoration of Wild-Type P53 in a Head and Neck Squamous Cellcarcinoma Cell Line","volume":"13","author":"Randis","year":"1998","journal-title":"Int J Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II Study of Single-Agent Panitumumab in Patients With Incurable Cutaneous Squamous Cell Carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for Patients With Incurable Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Clinical Trial","volume":"77","author":"William","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II Study of Cetuximab as First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.04.004","article-title":"Efficacy and Safety of Singleagent Pan-Human Epidermal Growth Factor Receptor (HER) Inhibitor Dacomitinib in Locally Advanced Unresectable or Metastatic Skin Squamous Cell Cancer","volume":"97","author":"Cavalieri","year":"2018","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e21033","article-title":"Treatment Patterns and Outcomes Among Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC) in a US Community Oncology Setting","volume":"37","author":"Cowey","year":"2019","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18703","article-title":"Treatment Patterns and Costs in Cutaneous Squamous Cell Carcinoma (CSCC) Patients With Nodal Dissection, Chemotherapy, and\/or Radiation Therapy","volume":"36","author":"Ruiz","year":"2018","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2014.08.005","article-title":"Ultraviolet Radiation-Induced Non-Melanoma Skin Cancer: Regulation of DNA Damage Repair and Inflammation","volume":"1","author":"Kim","year":"2014","journal-title":"Genes Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-Melanoma Skin Cancer","volume":"375","author":"Madan","year":"2010","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100 000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB Measurement in Clinical Practice: Considerations on Assay Requirements","volume":"4","author":"Buttner","year":"2019","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2614","article-title":"Ox40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate With Metastatic Potential","volume":"22","author":"Lai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.96","article-title":"Myeloid Dendritic Cells From Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation","volume":"129","author":"Bluth","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12728","article-title":"PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis","volume":"43","author":"Slater","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade With Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":":x25","DOI":"10.25251\/skin.2.supp.78","article-title":"Phase I Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up Efficacy and Safety Data [Abstract No 71P Plus Poster]","volume":"29","author":"Owonikoko","year":"2018","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in Locally Advanced Cutaneous Squamous Cell Carcinoma: Results From an Open-Label, Phase 2, Single-Arm Trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 Study of Cemiplimab in Patients With Metastatic Cutaneous Squamous Cell Carcinoma: Primary Analysis of Fixed-Dosing, Long-Term Outcome of Weight-Based Dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6015","article-title":"Primary Analysis of Phase 2 Results of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) [Abstract No. 6015 Plus Poster]","volume":"37","author":"Migden","year":"2019","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz255","article-title":"Phase 2 Study of 2 Dosing Regimens of Cemiplimab, a Human Monoclonal Anti\u2013PD-1, in Metastatic Cutaneous Squamous Cell Carcinoma (mCSCC) [Abstract Plus Poster]","volume":"30","author":"Rischin","year":"2019","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9526","article-title":"Phase 2 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Metastatic Cutaneous Squamous Cell Carcinoma (mCSCC; Group 1): 12-Month Follow-Up [Abstract No 9526 plus Poster]","volume":"37","author":"Guminski","year":"2019","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.4.1947","article-title":"The Role of CD80, CD86, and CTLA4 in Alloimmune Responses and the Induction of Long-Term Allograft Survival","volume":"162","author":"Judge","year":"1999","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00823.x","article-title":"CTLA4 Engagement Is Required for Induction of Murine Liver Transplant Spontaneous Tolerance","volume":"5","author":"Li","year":"2005","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"viii400","DOI":"10.1093\/annonc\/mdy288","article-title":"1208p PD-1 Blockade in Renal Transplant Patients With Poor Prognosis Cancer and Minimizing Risk of Organ Rejection Using Comprehensive Immune Monitoring and Screening Techniques: A Safety Study","volume":"29","author":"Carroll","year":"2018","journal-title":"Ann Oncol"},{"key":"B38","unstructured":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination Nivolumab and Ipilimumab or Nivolumab Alone in Melanoma Brain Metastases: A Multicentre Randomised Phase 2 Study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator\u2019s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal Replacement of Tumor-Specific T Cells Following PD-1 Blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant Versus Adjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women\u2019s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma","volume":"155","author":"Stamell Ruiz","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12967-017-1123-x","article-title":"A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma: Evaluation of Clinical and Immunologic Response","volume":"15","author":"DeWolf","year":"2017","journal-title":"J Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442166","article-title":"Efficacy of Combined Hypo-Fractionated Radiotherapy and Anti-PD-1 Monotherapy in Difficult-to-Treat Advanced Melanoma Patients","volume":"7","author":"Roger","year":"2018","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The Abscopal Effect of Local Radiotherapy: Using Immunotherapy to Make a Rare Event Clinically Relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121157","article-title":"Cd226 Opposes TIGIT to Disrupt Tregs in Melanoma","volume":"3","author":"Fourcade","year":"2018","journal-title":"JCI Insight"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12254-020-00673-2","article-title":"ASCO 2020 Non-Small Lung Cancer (NSCLC) Personal Highlights","volume":"13","author":"Horvath","year":"2021","journal-title":"Memo"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for Combining Immune Checkpoint Blockade With PARP Inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA Damage and Repair Biomarkers of Immunotherapy Response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T Cell Receptor Triggering","volume":"11","author":"van der Merwe","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/08923973.2014.890626","article-title":"Anti-CD40-Mediated Cancer Immunotherapy: An Update of Recent and Ongoing Clinical Trials","volume":"36","author":"Hassan","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming Oncolytic Viruses to Leverage Antitumor Immunity","volume":"15","author":"de Gruijl","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e22050","article-title":"An Open-Label, Single-Arm, Phase II Clinical Trial of RP1, an Enhanced Potency Oncolytic Herpes Virus, Combined With Nivolumab in Four Solid Tumor Types: Initial Results From the Skin Cancer Cohorts","volume":"38","author":"Middleton","year":"","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6803-0","article-title":"alimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience","volume":"25","author":"Perez","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.suc.2014.07.005","article-title":"Melanoma Vaccines: Mixed Past, Promising Future","volume":"94","author":"Ozao-Choy","year":"2014","journal-title":"Surg Clin North Am"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLG.0000158349.64337.ED","article-title":"Surgery and Adjuvant Radiotherapy in Patients With Cutaneous Head and Neck Squamous Cell Carcinoma Metastatic to Lymph Nodes: Combined Treatment Should be Considered Best Practice","volume":"115","author":"Veness","year":"2005","journal-title":"Laryngoscope"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708701","article-title":"Update on Keratinocyte Carcinomas","volume":"379","author":"Nehal","year":"2018","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot Evaluation of PD-1 Inhibition in Metastatic Cancerpatients With a History of Liver Transplantation: The Mayo Clinic Experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-Cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.727027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T21:37:07Z","timestamp":1674337027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.727027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":63,"alternative-id":["10.3389\/fonc.2021.727027"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.727027","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"727027"}}